Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant), By Major Markets, Vendor Landscape, And Segment Forecasts, 2018 - 2023
This report can be delivered to the clients within 5 Business Days
The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, according to a new report by Grand View Research, Inc., exhibiting a 14.3% CAGR during the forecast period. Several factors such as increase in investments for R&D, growing target population, and favorable government initiatives are anticipated to drive the market.
Currently available treatments for sickle cell disease (SCD) usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplant, and pharmacotherapy. Although bone marrow transplant is the only potentially curative treatment, it is recommended only to a small percentage of patients. The market has only two approved products—hydroxyurea and Endari.
High unmet medical needs, strong pipeline, and growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for SCD has increased owing to unavailability of a permanent cure and risks associated with bone marrow transplant.
Expected launch of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel is projected to drive the sickle cell disease market during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.
Further key findings from the report suggest:
The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, according to a new report by Grand View Research, Inc., exhibiting a 14.3% CAGR during the forecast period. Several factors such as increase in investments for R&D, growing target population, and favorable government initiatives are anticipated to drive the market.
Currently available treatments for sickle cell disease (SCD) usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplant, and pharmacotherapy. Although bone marrow transplant is the only potentially curative treatment, it is recommended only to a small percentage of patients. The market has only two approved products—hydroxyurea and Endari.
High unmet medical needs, strong pipeline, and growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for SCD has increased owing to unavailability of a permanent cure and risks associated with bone marrow transplant.
Expected launch of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel is projected to drive the sickle cell disease market during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.
Further key findings from the report suggest:
- Currently, 20 to 25 million people worldwide are reportedly living with sickle cell disease and about 300,000 infants are born annually with the disease
- U.S. dominated the global market and is projected to maintain its position through 2023, owing to rise in incidence of diseases and launch of promising pipeline candidates
- Among treatments, blood transfusion held the largest share in 2017, followed by pharmacotherapy. However, it is anticipated that pharmacotherapy will lead the market by 2023, supported by a strong pipeline and several promising drug launches
- Emmaus Medical, Global Blood Therapeutics, bluebird bio, Pfizer, and Novartis are some of the key players operating in this market
- Emmaus Medical is projected to dominate the SCD pharmaceutical market in 2023, supported by strong sales of Endari
- Currently, 37 pipeline drugs are in various clinical development stages and significant sales contribution is expected from promising candidates such as voxelotor (Global Blood Therapeutics), crizanlizumab (Novartis), Altemia (Sancilio), and rivipansel (Pfizer).
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types
3.1.1.1 Genotypic variants
3.1.1.2 Phenotypic variants
3.1.2 Diagnosis
3.1.3 Current Treatment
3.2 Epidemiology
3.2.1 U.S.
3.2.2 Japan
3.2.3 Germany
3.2.4 U.K.
3.2.5 France
3.2.6 Italy
3.2.7 Spain
3.2.8 RoW
CHAPTER 4 GLOBAL SICKLE CELL DISEASE MARKET OVERVIEW
4.1 Market, by Treatment
4.1.1 Blood Transfusion
4.1.2 Pharmacotherapy
4.1.3 Bone Marrow Transplant
4.2 Market, by Major Markets
4.2.1 U.S.
4.2.2 Japan
4.2.3 Germany
4.2.4 U.K.
4.2.5 France
4.2.6 Italy
4.2.7 Spain
4.2.8 RoW
4.3 Market Size & Forecast
4.3.1 Sales performance
4.3.1.1 Sales performance, by treatment (2017 - 2023)
4.3.1.2 Sales performance, by major markets (2017 - 2023)
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Schedule
4.6 Sickle Cell Disease Market: Drivers and Restraints
4.6.1 Market Drivers
4.6.2 Market Restraints
4.7 M&A, Deal Landscape (2014-2018 YTD)
4.8 SWOT
CHAPTER 5 GLOBAL SICKLE CELL DISEASE MARKET: PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.2 Key R&D trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late stage pipeline analysis
5.2.2 Profile of disruptive drugs
5.2.2.1 Voxelotor (GBT 440)
5.2.2.2 Crizanlizumab (SEG 101)
5.2.2.3 Rivipansel (PF 6460031)
5.2.2.4 Lentiglobin (BB 305)
5.2.2.5 Rivogenlecleucel (BPX 501)
5.2.2.6 Sevuparin (DF-02)
5.2.2.7 Sanguinate (PEG-COHb)
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Emmaus Life Sciences
6.1.1 Company Overview
6.1.2 Current Product Portfolio-Major Products
6.1.3 Product Forecast Sales up to 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 SWOT
6.2 Global Blood Therapeutics
6.2.1 Company Overview
6.2.2 Current Product Portfolio-Major Products
6.2.3 Product Forecast Sales up to 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 SWOT
6.3 Bluebird Bio
6.3.1 Company Overview
6.3.2 Current Product Portfolio-Major Products
6.3.3 Product Forecast Sales up to 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 SWOT
6.4 Pfizer
6.4.1 Company Overview
6.4.2 Current Product Portfolio-Major Products
6.4.3 Product Forecast Sales up to 2023
6.4.4 Strategic Initiatives (Pfizer)
6.4.4.1 Key Company News Flow
6.4.5 SWOT
6.5 Novartis
6.5.1 Company Overview
6.5.2 Current Product Portfolio-Major Products
6.5.3 Product Forecast Sales up to 2023
6.5.4 Strategic Initiatives (Novartis)
6.5.4.1 Key Company News Flow
6.5.5 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 Winners and Losers
7.3 Emerging Companies
7.3.1 Prolong Pharmaceuticals
7.3.2 Modus Therapeutics
7.3.3 Bellicum Pharmaceuticals
7.3.4 Gamida Cell
7.4 The Road Ahead
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types
3.1.1.1 Genotypic variants
3.1.1.2 Phenotypic variants
3.1.2 Diagnosis
3.1.3 Current Treatment
3.2 Epidemiology
3.2.1 U.S.
3.2.2 Japan
3.2.3 Germany
3.2.4 U.K.
3.2.5 France
3.2.6 Italy
3.2.7 Spain
3.2.8 RoW
CHAPTER 4 GLOBAL SICKLE CELL DISEASE MARKET OVERVIEW
4.1 Market, by Treatment
4.1.1 Blood Transfusion
4.1.2 Pharmacotherapy
4.1.3 Bone Marrow Transplant
4.2 Market, by Major Markets
4.2.1 U.S.
4.2.2 Japan
4.2.3 Germany
4.2.4 U.K.
4.2.5 France
4.2.6 Italy
4.2.7 Spain
4.2.8 RoW
4.3 Market Size & Forecast
4.3.1 Sales performance
4.3.1.1 Sales performance, by treatment (2017 - 2023)
4.3.1.2 Sales performance, by major markets (2017 - 2023)
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Schedule
4.6 Sickle Cell Disease Market: Drivers and Restraints
4.6.1 Market Drivers
4.6.2 Market Restraints
4.7 M&A, Deal Landscape (2014-2018 YTD)
4.8 SWOT
CHAPTER 5 GLOBAL SICKLE CELL DISEASE MARKET: PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.2 Key R&D trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late stage pipeline analysis
5.2.2 Profile of disruptive drugs
5.2.2.1 Voxelotor (GBT 440)
5.2.2.2 Crizanlizumab (SEG 101)
5.2.2.3 Rivipansel (PF 6460031)
5.2.2.4 Lentiglobin (BB 305)
5.2.2.5 Rivogenlecleucel (BPX 501)
5.2.2.6 Sevuparin (DF-02)
5.2.2.7 Sanguinate (PEG-COHb)
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Emmaus Life Sciences
6.1.1 Company Overview
6.1.2 Current Product Portfolio-Major Products
6.1.3 Product Forecast Sales up to 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 SWOT
6.2 Global Blood Therapeutics
6.2.1 Company Overview
6.2.2 Current Product Portfolio-Major Products
6.2.3 Product Forecast Sales up to 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 SWOT
6.3 Bluebird Bio
6.3.1 Company Overview
6.3.2 Current Product Portfolio-Major Products
6.3.3 Product Forecast Sales up to 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 SWOT
6.4 Pfizer
6.4.1 Company Overview
6.4.2 Current Product Portfolio-Major Products
6.4.3 Product Forecast Sales up to 2023
6.4.4 Strategic Initiatives (Pfizer)
6.4.4.1 Key Company News Flow
6.4.5 SWOT
6.5 Novartis
6.5.1 Company Overview
6.5.2 Current Product Portfolio-Major Products
6.5.3 Product Forecast Sales up to 2023
6.5.4 Strategic Initiatives (Novartis)
6.5.4.1 Key Company News Flow
6.5.5 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 Winners and Losers
7.3 Emerging Companies
7.3.1 Prolong Pharmaceuticals
7.3.2 Modus Therapeutics
7.3.3 Bellicum Pharmaceuticals
7.3.4 Gamida Cell
7.4 The Road Ahead
LIST OF TABLES
Table 1 Sales Performance, by Treatment (in $ million)
Table 2 Sales Performance, by Major Markets (in $ million)
Table 3 U.S. Patent Expiry Schedule
Table 4 R&D Pipeline Overview
Table 5 Late Stage Pipeline
Table 6 Product Profile: Voxelotor (GBT 440)
Table 7 Product Profile: Crizanlizumab (SEG 101)
Table 8 Product Profile: Rivipansel (PF 6460031)
Table 9 Product Profile: Lentiglobin (BB 305)
Table 10 Product Profile: Rivogenlecleucel (BPX 501)
Table 11 Product Profile: Sevuparin (DF-02)
Table 12 Product Profile: Sanguinate (PEG-COHb)
Table 13 Global Pipeline Forecast
Table 14 Product Portfolio: Endari
Table 15 Endari Sales Forecast, 2017 - 2023 (in $ million)
Table 16 Product Portfolio: Voxelotor
Table 17 Voxelotor Sales Forecast, 2017 - 2023 (in $ million)
Table 18 Product Portfolio: Lentiglobin
Table 19 Lentiglobin Sales Forecast, 2017 - 2023 (in $ million)
Table 20 Product Portfolio: Rivipansel
Table 21 Product Portfolio: PF-04447943
Table 22 Rivipansel Sales Forecast, 2017 - 2023 (in $ million)
Table 23 Product Portfolio: Crizanlizumab
Table 24 Crizanlizumab Sales Forecast, 2017 - 2023 (in $ million)
Table 1 Sales Performance, by Treatment (in $ million)
Table 2 Sales Performance, by Major Markets (in $ million)
Table 3 U.S. Patent Expiry Schedule
Table 4 R&D Pipeline Overview
Table 5 Late Stage Pipeline
Table 6 Product Profile: Voxelotor (GBT 440)
Table 7 Product Profile: Crizanlizumab (SEG 101)
Table 8 Product Profile: Rivipansel (PF 6460031)
Table 9 Product Profile: Lentiglobin (BB 305)
Table 10 Product Profile: Rivogenlecleucel (BPX 501)
Table 11 Product Profile: Sevuparin (DF-02)
Table 12 Product Profile: Sanguinate (PEG-COHb)
Table 13 Global Pipeline Forecast
Table 14 Product Portfolio: Endari
Table 15 Endari Sales Forecast, 2017 - 2023 (in $ million)
Table 16 Product Portfolio: Voxelotor
Table 17 Voxelotor Sales Forecast, 2017 - 2023 (in $ million)
Table 18 Product Portfolio: Lentiglobin
Table 19 Lentiglobin Sales Forecast, 2017 - 2023 (in $ million)
Table 20 Product Portfolio: Rivipansel
Table 21 Product Portfolio: PF-04447943
Table 22 Rivipansel Sales Forecast, 2017 - 2023 (in $ million)
Table 23 Product Portfolio: Crizanlizumab
Table 24 Crizanlizumab Sales Forecast, 2017 - 2023 (in $ million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 U.S. Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 8 Japan Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 9 Germany Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 10 U.K. Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 11 France Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 12 Italy Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 13 Spain Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 14 RoW Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 15 Sickle Cell Disease Market Share, by Treatment (2017 & 2023)
Fig. 16 Sickle Cell Disease Market Share, by Country (2017 & 2023)
Fig. 17 U.S. Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 18 Japan Sickle Cell Disease Market, $ thousand (2017 - 2023)
Fig. 19 Germany Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 20 U.K. Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 21 France Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 22 Italy Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 23 Spain Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 24 RoW Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 25 Sickle Cell Disease Market Size & Forecast, $ million (2017 - 2023)
Fig. 26 Global Sickle Cell Disease Market SWOT
Fig. 27 Sickle Cell Disease R&D Pipeline - Drugs in Development
Fig. 28 SWOT Analysis (Emmaus Life Sciences)
Fig. 29 SWOT Analysis (Global Blood Therapeutics)
Fig. 30 SWOT Analysis (Bluebird Bio)
Fig. 31 SWOT Analysis (Pfizer)
Fig. 32 SWOT Analysis (Novartis)
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 U.S. Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 8 Japan Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 9 Germany Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 10 U.K. Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 11 France Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 12 Italy Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 13 Spain Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 14 RoW Forecast Sickle Cell Disease Prevalence (2017 - 2023)
Fig. 15 Sickle Cell Disease Market Share, by Treatment (2017 & 2023)
Fig. 16 Sickle Cell Disease Market Share, by Country (2017 & 2023)
Fig. 17 U.S. Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 18 Japan Sickle Cell Disease Market, $ thousand (2017 - 2023)
Fig. 19 Germany Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 20 U.K. Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 21 France Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 22 Italy Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 23 Spain Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 24 RoW Sickle Cell Disease Market, $ million (2017 - 2023)
Fig. 25 Sickle Cell Disease Market Size & Forecast, $ million (2017 - 2023)
Fig. 26 Global Sickle Cell Disease Market SWOT
Fig. 27 Sickle Cell Disease R&D Pipeline - Drugs in Development
Fig. 28 SWOT Analysis (Emmaus Life Sciences)
Fig. 29 SWOT Analysis (Global Blood Therapeutics)
Fig. 30 SWOT Analysis (Bluebird Bio)
Fig. 31 SWOT Analysis (Pfizer)
Fig. 32 SWOT Analysis (Novartis)
